Literature DB >> 30385492

Ibrutinib and Aspergillus: a Btk-targeted risk.

Jennifer A Woyach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30385492     DOI： 10.1182/blood-2018-08-865659

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

Review 1.  Bruton Tyrosine Kinase Inhibitors: Present and Future.

Authors:  Jan A Burger
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 2.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

3.  A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.

Authors:  Emily M Eichenberger; Jennifer Saullo; Danielle Brander; Shih-Hsiu Wang; John R Perfect; Julia A Messina
Journal:  Med Mycol Case Rep       Date:  2019-12-05

4.  The robust and rapid role of molecular testing in precision fungal diagnostics: A case report.

Authors:  Julie M Steinbrink; David K Hong; Stephen P Bergin; Rami N Al-Rohil; John R Perfect; Eileen K Maziarz
Journal:  Med Mycol Case Rep       Date:  2020-02-13

5.  Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature.

Authors:  Martin Fehr; Gieri Cathomas; Anne Graber; Eva Makert; Elisabeth Gaus; Katia Boggian
Journal:  Med Mycol Case Rep       Date:  2019-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.